Selank Amidate · Research brief

Semax vs Noopept: Is Noopept a Racetam?

Real Peptides Research TeamEditorial

Updated September 30, 20269 min read

57 WORDS

Short answer

Noopept sits in the racetam section of nearly every nootropic forum thread, vendor menu and stack spreadsheet online. Chemically, it doesn't belong there. Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, coded GVS-111 during its development in Russia) is a proline-containing dipeptide that was designed as a peptide analogue of piracetam, which is a very different statement from being a racetam.

Key takeaways

Noopept is a dipeptide ethyl ester, not a racetam; the pyrrolidine ring in its proline residue is what creates the mistaken classification.
Semax is a seven-amino-acid analogue of the ACTH(4-10) fragment with a Pro-Gly-Pro tail added for enzymatic stability, and it lacks the cortisol-releasing activity of full ACTH.
Any valid semax vs noopept comparison must control for route, because peptidases degrade Semax orally while noopept's ester is orally active in animal models.
Noopept's main metabolite, cycloprolylglycine, is an endogenous brain dipeptide, and rodent studies report increased hippocampal BDNF and NGF mRNA expression.
Noopept is not an approved therapeutic good in Australia and is generally treated as prescription-class under the Poisons Standard, so consumer importation isn't lawful.
Selank shares Semax's Pro-Gly-Pro stabilising motif and tuftsin lineage, which makes it the more logical structural comparator than noopept.

We supply research-grade compounds to laboratories, and misclassification is the single most common thing we end up correcting in conversations about these two molecules. Get the chemistry wrong and the storage, handling and experimental route usually go wrong with it.

Semax vs noopept: what's the difference, and is noopept a racetam?

Semax vs noopept compares a synthetic heptapeptide against a dipeptide ester. Semax is an ACTH(4-10) fragment analogue carrying an added Pro-Gly-Pro tail. Noopept is a two-amino-acid ethyl ester and not a true racetam. Both are research-use-only compounds in the United States, studied preclinically for neurotrophic and neuroprotective endpoints.

Here's the oversimplification worth killing early: people treat semax vs noopept as two versions of the same idea, one injectable and one oral. They share almost no chemistry, and their published literature comes from largely separate research traditions. This article covers the classification question, what the BDNF and NGF findings actually say, where Selank fits as the third entity, and how regulatory status changes by country.

Two molecules, two completely different chemical families

Neither compound is a racetam, and they aren't in the same chemical family as each other either. Semax is a synthetic heptapeptide, seven amino acids long: Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues reproduce the 4-10 fragment of adrenocorticotropic hormone (ACTH), the pituitary hormone that normally triggers cortisol release, while the C-terminal Pro-Gly-Pro tripeptide was added to slow enzymatic degradation. The analogue does not carry the corticotropic activity of full-length ACTH.

Noopept is two amino acids: a phenylacetylated proline joined to glycine and capped as an ethyl ester. The racetam label is a visual mistake. Proline contains a five-membered pyrrolidine ring, and racetams are built on a 2-oxo-pyrrolidine acetamide scaffold. Similar ring, different molecule, different family. So when a researcher asks 'is noopept a racetam' before ordering, the accurate answer in a semax vs noopept discussion is no: it's a dipeptide inspired by racetam design, sharing a structural motif rather than a drug class.

Is noopept a stimulant? The literature characterises it as a nootropic and neuroprotective agent, not a psychostimulant. There's no documented amphetamine-style monoamine release or reuptake blockade. Animal reports describe mild activating and anxiolytic-like features, which is not stimulant pharmacology. In our experience, labs that start from the structure rather than the marketing category rarely make route or storage errors later.

What the published literature actually reports about each

The research bases differ as much as the structures do. Noopept's principal metabolite is cycloprolylglycine (CPG), a dipeptide occurring endogenously in brain tissue, and rodent work reports increased expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) messenger RNA in the hippocampus following repeated administration. Semax research, largely Russian, reports changes in BDNF and its receptor trkB in rat hippocampus alongside effects on brain gene expression and monoamine systems in ischemia models. Semax is registered as a medicine in Russia; it is not FDA-approved.

Does noopept work? Honestly, the evidence base is thinner than its reputation suggests. Most of it is preclinical or small clinical work published in Russian-language journals with limited independent replication, which justifies further research rather than efficacy claims.

The design error we correct most often in a semax vs noopept study isn't concentration, it's route. Semax is a peptide, so gastrointestinal peptidases hydrolyse it before meaningful absorption, which is why nearly all published work uses intranasal or parenteral routes. Noopept's ethyl ester survives oral administration in animal models, which is the entire point of the ester. Put both in a single oral-gavage arm and you're measuring an intact dipeptide against a partly digested peptide, then attributing the gap to pharmacology. That's a chemistry artefact wearing a result's clothing.

Where Selank fits, and why legality depends on your jurisdiction

Selank is the third entity people are usually circling. It's a heptapeptide analogue of tuftsin, the immunomodulatory tetrapeptide, and it carries the same stabilising Pro-Gly-Pro tail as Semax. Its research skews toward anxiolytic-like and GABA- or monoamine-related endpoints rather than cognition-first measures. Mapping semax vs selank vs noopept honestly: two regulatory peptides sharing a design lineage, plus one orally active dipeptide from an unrelated program.

Regulatory status is where researchers get caught out. In the United States, all three are research-use-only chemicals, not approved drugs and not dietary supplements. Is noopept legal in Australia? Not as a consumer product. It isn't an approved therapeutic good, nootropics of this class are generally captured as prescription-only substances under the Poisons Standard, and personal importation without authorisation isn't lawful. Confirm the current entry with the TGA and clear research imports through your institution's compliance office, because scheduling changes.

This material is educational, describing published research and laboratory handling rather than medical guidance, and none of these compounds are approved for human use. They are supplied for laboratory research only and never for human or animal consumption. If your question concerns an animal's health, talk to your veterinarian rather than a peptide supplier. Our team ships every vial with batch-specific analytical documentation for exactly this reason: a comparison is only as good as the identity and purity of what's in the vial.

Semax vs Noopept: Side-by-Side Research Comparison

This table summarises the attributes that actually change experimental design in a semax vs noopept comparison, rather than the marketing descriptors. Chemistry, route stability and regulatory class are the three that determine whether your data means anything.

Attribute	Semax	Noopept	Bottom Line for Researchers
Chemical class	Synthetic heptapeptide, ACTH(4-10) analogue with Pro-Gly-Pro extension	Proline-glycine dipeptide ethyl ester, piracetam-inspired but not a racetam	Different families entirely, so shared handling assumptions don't transfer
Route stability	Degraded by gastrointestinal peptidases; published work uses intranasal or parenteral routes	Ester survives oral administration in animal studies	Never place both compounds in a single oral arm; you'd be testing degradation, not activity
Reported mechanistic focus	BDNF and trkB expression changes, monoamine and gene expression effects in ischemia models	Cycloprolylglycine metabolite, reported BDNF and NGF mRNA increases in hippocampus	Both touch neurotrophic signalling, but through unrelated upstream chemistry
Evidence maturity	Registered as a medicine in Russia; not FDA-approved; limited Western replication	Mostly Russian preclinical and small clinical work; limited independent replication	Treat published effect sizes as hypothesis-generating, not settled
Regulatory status	Research-use-only in the United States; restricted in several jurisdictions	Research-use-only in the United States; prescription-class in Australia under the Poisons Standard	Verify jurisdiction before purchase, not after customs holds a shipment
Documentation to demand	Batch-specific certificate of analysis with sequence confirmation	Batch-specific certificate of analysis with purity and identity data	No certificate, no comparison worth publishing

What If: Research Design Scenarios

What if I want to study semax and noopept together in one protocol?

Run it as a factorial design with separate single-compound arms, not as a combined arm compared against controls. There is no published controlled co-administration data on semax and noopept together, so a combination-only design can't separate additive effects from interaction effects or from route artefacts. Mechanistically the two reach neurotrophic endpoints by different upstream chemistry, which is precisely why the interaction term matters. Build the arms so the answer is interpretable before you buy material.

What if my supplier can't produce a batch-specific certificate of analysis?

Don't order. Identity and purity data are the only way to know whether a vial labelled Semax contains the correct seven-residue sequence rather than a truncated fragment. Sequence errors and low-purity lots don't announce themselves visually, and a failed comparison traced back to unverified material wastes an entire study cycle. Every batch we release is paired with analytical documentation, and our certificates of analysis are published rather than promised on request.

What if the Semax arrived as a liquid spray and the noopept as a powder?

Handle them as two different stability problems. Lyophilised peptide powder is typically held at around minus 20 degrees Celsius before reconstitution, while solutions are generally kept refrigerated at 2 to 8 degrees Celsius and protected from light and repeated temperature cycling. Peptide bonds hydrolyse in solution over time; the powder doesn't. Log receipt temperature and storage conditions, because an unrecorded warm excursion is the quietest source of irreproducible data in peptide research.

The Unglamorous Truth About Comparing These Two Compounds

Let's be direct about this: most of the semax vs noopept content online compares two literatures, not two compounds. One is a Russian regulatory peptide with intranasal-route research behind it. The other is an orally active dipeptide from a separate development program with modest, largely unreplicated evidence. Ranking them against each other for a generic goal like focus is pharmacologically meaningless. The useful question is which chemistry fits your endpoint, your route and your jurisdiction.

If you're building out a peptide research line, the background reading on Semax and Selank covers the sequence and stability details in more depth, and the catalog pages for Semax liquid spray, Semax amidate, Selank liquid spray, Selank amidate, our oral research compounds and the wider research catalog list format and documentation for each.

The semax vs noopept question almost always starts as a ranking exercise and ends as a chemistry lesson. A heptapeptide and a dipeptide ester aren't rivals; they're different tools that happen to have been filed in the same internet category by people who never looked at either structure. Once you can name the sequence, the metabolite and the reason one survives the gut, the comparison stops being a debate and becomes a design decision. That shift is the whole value of asking the question properly.

References

Peer-reviewed sources on Semax indexed in PubMed, listed for research context. Real Peptides supplies Semax for laboratory research use only.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae, 2025. PMID 41479572. doi:10.32607/actanaturae.27808
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications, 2025. PMID 40496623. doi:10.1155/bca/4226220
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020. PMID 32580520. doi:10.3390/genes11060681
Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine, 2017. PMID 28577097. doi:10.1007/s10517-017-3748-4
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017. PMID 28702721. doi:10.1134/S0012496617030048
Semax prevents learning and memory inhibition by heavy metals. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. PMID 27411820. doi:10.1134/S0012496616030066
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of molecular neuroscience : MN, 2011. PMID 20617398. doi:10.1007/s12031-010-9421-2

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

No. Noopept is N-phenylacetyl-L-prolylglycine ethyl ester, a dipeptide designed in Russia as a peptide analogue of piracetam. True racetams share a 2-oxo-pyrrolidine acetamide scaffold, while noopept only contains a similar five-membered pyrrolidine ring inside its proline residue. Shared motif, different chemical class.

The published evidence is largely Russian preclinical and small clinical work with limited independent replication, so research suggests neurotrophic activity rather than confirming it. Rodent studies report increased hippocampal BDNF and NGF messenger RNA expression and point to the endogenous metabolite cycloprolylglycine. That's hypothesis-generating data, not established efficacy.

No. The literature describes noopept as a nootropic and neuroprotective compound rather than a psychostimulant, and there is no documented amphetamine-style monoamine release or reuptake inhibition. Animal reports mention mild activating and anxiolytic-like characteristics, which reflects different pharmacology from stimulant drugs acting directly on catecholamine transporters.

Not as a consumer product. Noopept is not an approved therapeutic good in Australia, and nootropics of this class are generally captured as prescription-only substances under the Poisons Standard, so personal importation without authorisation isn't lawful. Scheduling changes, so verify the current TGA entry and institutional import requirements first.

Semax is supplied as a lyophilised peptide or a prepared solution and, in published research, is administered intranasally or parenterally because gastrointestinal peptidases hydrolyse it. Noopept's ethyl ester is orally active in animal models. Powder is typically stored near minus 20 degrees Celsius; solutions are refrigerated at 2 to 8 degrees Celsius.

They can be included in one study, but only as a factorial design with separate single-compound arms. No published controlled data exists on semax and noopept together, so a combination-only arm cannot separate additive from interactive effects. Their upstream chemistry differs entirely, which is exactly why the interaction term needs measuring.

Pricing varies widely by supplier, format, quantity and purity grade, so treat any single quoted figure with suspicion. What should not vary is documentation: every vial needs a batch-specific certificate of analysis confirming identity, sequence and purity. Without that, a semax vs noopept comparison has no verified starting material.

The main laboratory risks are misidentification, contamination during reconstitution and stability loss from temperature cycling. Peptide bonds hydrolyse in solution over time, and warm excursions during shipping can't be detected visually. These compounds are research-use-only, are not approved drugs, and are not for human or animal consumption.

Selank is the compound whose literature focuses most on anxiolytic-like endpoints. It's a heptapeptide analogue of the tetrapeptide tuftsin, sharing the Pro-Gly-Pro stabilising tail used in Semax, with research touching GABA- and monoamine-related pathways. Semax research leans toward neurotrophic and ischemia models; noopept toward BDNF and NGF expression.

Noopept's ethyl ester cap and two-residue length let it survive gastrointestinal peptidase activity long enough for absorption, after which it's metabolised to cycloprolylglycine. Semax is a seven-residue peptide, and even with its Pro-Gly-Pro stabilising tail it's cleaved before meaningful systemic exposure, which is why published work uses intranasal or parenteral routes.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA